Literature DB >> 16060832

Regulated production and anti-HIV type 1 activities of cytidine deaminases APOBEC3B, 3F, and 3G.

Kristine M Rose1, Mariana Marin, Susan L Kozak, David Kabat.   

Abstract

APOBEC3G and 3F (A3G and A3F) cytidine deaminases incorporate into retroviral cores where they lethally hypermutate nascent DNA reverse transcripts. As substantiated here, the viral infectivity factor (Vif) encoded by human immunodeficiency virus type-1 (HIV-1) binds A3G and A3F and induces their degradation, thereby precluding their incorporation into viral progeny. Previous evidence suggested that A3G is expressed in H9 and other nonpermissive cells that contain this antiviral defense but not in several permissive cells, and that overexpression of A3G or A3F makes permissive cells nonpermissive. Using a broader panel of cell lines, we confirmed a correlation between A3G and cellular abilities to inactivate HIV-1(Deltavif). However, there was a quantitative discrepancy because several cells with weak antiviral activities had similar amounts of wild-type A3G mRNA and protein compared to H9 cells. Antiviral activity of H9 cells was also attenuated in some conditions. These quantitative discrepancies could not be explained by the presence of A3F or other A3G paralogs in some of the cell lines. Thus, A3A, A3B, and A3C had weak but significant anti-HIV-1 activities and did not dominantly interfere with A3G or A3F antiviral functions. Control of A3G synthesis by the protein kinase C/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathway was also similar in permissive and nonpermissive cells. A3G in highly permissive cells is degraded by Vif, suggesting that it is not in a sequestered site, and is specifically incorporated in low amounts into HIV-1(Deltavif). Although A3G and/or A3F inactivate HIV-1(Deltavif) and are neutralized by Vif, the antiviral properties of cell lines are also influenced by other cellular and viral factors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16060832     DOI: 10.1089/aid.2005.21.611

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  36 in total

1.  Leveraging APOBEC3 proteins to alter the HIV mutation rate and combat AIDS.

Authors:  Judd F Hultquist; Reuben S Harris
Journal:  Future Virol       Date:  2009-11-01       Impact factor: 1.831

Review 2.  Role and mechanism of action of the APOBEC3 family of antiretroviral resistance factors.

Authors:  Bryan R Cullen
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

3.  Myeloid differentiation and susceptibility to HIV-1 are linked to APOBEC3 expression.

Authors:  Gang Peng; Teresa Greenwell-Wild; Salvador Nares; Wenwen Jin; Ke Jian Lei; Zoila G Rangel; Peter J Munson; Sharon M Wahl
Journal:  Blood       Date:  2007-03-19       Impact factor: 22.113

4.  APOBEC3F and APOBEC3G mRNA levels do not correlate with human immunodeficiency virus type 1 plasma viremia or CD4+ T-cell count.

Authors:  Soo-Jin Cho; Henning Drechsler; Ryan C Burke; Max Q Arens; William Powderly; Nicholas O Davidson
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

Review 5.  Host restriction factors blocking retroviral replication.

Authors:  Daniel Wolf; Stephen P Goff
Journal:  Annu Rev Genet       Date:  2008       Impact factor: 16.830

6.  Cellular microRNA expression correlates with susceptibility of monocytes/macrophages to HIV-1 infection.

Authors:  Xu Wang; Li Ye; Wei Hou; Yu Zhou; Yan-Jian Wang; David S Metzger; Wen-Zhe Ho
Journal:  Blood       Date:  2008-11-17       Impact factor: 22.113

7.  D316 is critical for the enzymatic activity and HIV-1 restriction potential of human and rhesus APOBEC3B.

Authors:  Rebecca M McDougle; Judd F Hultquist; Alex C Stabell; Sara L Sawyer; Reuben S Harris
Journal:  Virology       Date:  2013-03-29       Impact factor: 3.616

8.  APOBEC3G restricts HIV-1 to a greater extent than APOBEC3F and APOBEC3DE in human primary CD4+ T cells and macrophages.

Authors:  Chawaree Chaipan; Jessica L Smith; Wei-Shau Hu; Vinay K Pathak
Journal:  J Virol       Date:  2012-10-24       Impact factor: 5.103

9.  Exosomes packaging APOBEC3G confer human immunodeficiency virus resistance to recipient cells.

Authors:  Atanu K Khatua; Harry E Taylor; James E K Hildreth; Waldemar Popik
Journal:  J Virol       Date:  2008-11-05       Impact factor: 5.103

10.  APOBEC3B deletion and risk of HIV-1 acquisition.

Authors:  Ping An; Randall Johnson; John Phair; Gregory D Kirk; Xiao-Fang Yu; Sharyne Donfield; Susan Buchbinder; James J Goedert; Cheryl A Winkler
Journal:  J Infect Dis       Date:  2009-10-01       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.